Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 116,712 shares at $15.01 ($1.8M) on 2024-02-14, disclosed to the SEC on 2024-02-16.
Open-market sale of $1.8M KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.01 | 58,356 | $876K | 50.0% |
| 2 | $15.01 | 58,356 | $876K | 50.0% |
| Total | $15.01 avg | 116,712 | $1.8M | 100% |
| Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |
| KALV | SELL | 2023-08-21 | $319K | — | Filing → |